Predict your next investment

Corporation
HEALTHCARE | Biotechnology
imaxio.com

See what CB Insights has to offer

Founded Year

2000

Stage

Unattributed | Alive

Total Raised

$7.62M

Last Raised

$3.77M | 9 yrs ago

About Imaxio

Imaxio is an integrated biotech company focused on vaccines and genomics, and based on the combination of R&D and commercial activities:MX313: a technology platform using recombinant carrier proteins to develop immunostimulant vaccines against several infectious diseases.SPIROLEPT: a vaccine against human leptospirosis marketed in France.GENOMICS: high throughput genomic applications for the development of companion diagnostic tests in oncology and immunology.Its development is based on the growth of its products and services revenues, as well as on acquisition of synergistic products and technologies, to sustain R&D programs. Imaxio was formed in 2006 by the merger of Diagnogene and Avidis (a spin-off developed in 2000 by the Medical Research Council and the University of Cambridge in the UK).

Imaxio Headquarter Location

181 - 203, avenue Jean Jaures

69007,

France

+33(0)4 37 65 55 00

Latest Imaxio News

Osivax, a clinical-stage biotech focused on vaccines, announces the closing of a EUR2.7M seed funding round - OSIVAX

Jul 10, 2019

Osivax, a clinical-stage biotech focused on vaccines, announces the closing of a EUR2.7M seed funding round ​June 15th, 2017 in Lyon (France) Osivax was recently created as a spin-off of Imaxio (Lyon, France) ​and has just finalized a EUR 2.7 million seed funding round Lyon, France – June 15th, 2017 – Osivax, a clinical-stage biotech start’up focused on vaccines and based in Lyon (France), announces today the closing of a seed funding round of EUR 2.7 million. Osivax was recently created as a spin-off of the R&D department of Imaxio, a biotech company also based in Lyon. The objectives of the spin-off are to enable Osivax to focus on the development of the R&D platform and Imaxio to accelerate the commercial development of its leptospirosis vaccine commercialized currently in France and soon internationally. Osivax develops a clinical-stage pipeline of vaccines and immunotherapies based on the oligoDOM® technology. oligoDOM® is a pro-immunogenic antigen reengineering technology which has been developed over the last 15 years by Imaxio. It is protected by a portfolio of 4 patent families, now owned by Osivax. Osivax pipeline is composed of a malaria vaccine candidate currently in phase I clinical trial, an influenza vaccine candidate expected to enter in phase I in early 2018, and other vaccine & immunotherapy candidates in research stage. The EUR 2.7 million funds raised by Osivax will enable it to accelerate the clinical development of its influenza vaccine candidate and start a phase I trial in early 2018. Osivax was recently founded by Mr. Alexandre Le Vert (CEO), Dr. Florence Nicolas (Development Director) and Dr. Fergal Hill (Chief Scientific Officer). Before founding Osivax, the three founders were working at IMAXIO, where Dr Fergal Hill was the inventor of the oligoDOM® technology now owned by Osivax. Pradeyrol Développement, a French family office based in Paris and Imaxio’s majority shareholder, has participated in the fundraising. Other terms of the fundraising are not disclosed. “This fundraising is a key milestone for the development of our oligoDOM®- based vaccine pipeline,” said Alexandre Le Vert, Chairman and Chief Executive Officer of Osivax. “These funds will help us accelerate the clinical development of our influenza candidate with a phase I clinical trial expected to start in early 2018.” “The creation of Osivax and this fundraising are relevant enablers to accelerate the 15 years research performed within Imaxio,” added Dr. Christian Pradeyrol, Chairman of Imaxio’s Board and an investor in Osivax. “Osivax has got the right team, the right focus and the right funding to accelerate the development of the oligoDOM®-based pipeline, starting with the Influenza candidate which should enter the clinic in early 2018.” About Imaxio: ​Imaxio is a small commercial stage biotech company specialized in immunology, which commercializes a human vaccine against an occupational disease caused by leptospira icterohaemorrhagiae. In 2016, its revenue was 2.3M€. For further information : www.imaxio.com ​ About Osivax Osivax’s mission is to revolutionize influenza prevention with a universal flu vaccine for both current and future Influenza A and B infections by leveraging its unique oligoDOM® technology platform. The most advanced candidate, a broad-spectrum A-strain flu vaccine is in Phase 1 clinical development. Osivax is focused on providing proof-of-concept in Influenza A firstly to save lives and secondly to lay the groundwork for a universal flu vaccine as well as apply the platform to other infectious and immune system-associated diseases. For further information:  www.osivax.com

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Imaxio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Imaxio is included in 2 Expert Collections, including Cancer.

C

Cancer

3,592 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Imaxio Patents

Imaxio has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2015

5/8/2018

Influenza, Vaccines, Virology, Immunology, Virus families

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/21/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/8/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Influenza, Vaccines, Virology, Immunology, Virus families

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.